Alex Philippidis

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, in a deal designed to broaden the buyer’s ophthalmology pipeline with Perfuse’s sole pipeline drug and two clinical phase programs for eye disorders.

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene therapy designed to restore a neurosensory function to normal levels.

EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is among drug candidates for nonmuscle invasive bladder cancer (NMIBC)—and how questions over clinical data are enough to send investors scurrying to sell their shares.

10x Genomics and Harvard University have sued Element Biosciences, alleging that Element’s AVITI24™ multiomics platform, Teton chemistry, and related services infringe on four university-owned patents exclusively licensed by the genomics and sequencing tools giant—while Element has denied wrongdoing and promises to fight the lawsuit.

Bristol Myers Squibb (BMS) will partner with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, and immunology, through a collaboration that could generate more than $15.2 billion for the Chinese drug developer.

Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates encompassing a new form of antibody-drug conjugates aimed at challenging and historically undruggable targets, through a strategic research collaboration that could generate up to $2.3 billion-plus for the Cambridge, MA, biotech.

Credit: PhonlamaiPhoto/ Getty Images Touching Base Touching Base is the dynamic podcast series from the editors of GEN . Each episode

Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an IPO.

Eli Lilly has agreed to acquire three privately-held developers of vaccines for infectious diseases for a combined up-to-$3.83 billion cash, in deals intended to expand the acquisitive pharma giant’s R&D efforts into infectious disease.

Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, through a collaboration that could generate up to $10.5 billion for the Chinese biotech.